Johnson & Johnson (NYSE:JNJ) subsidiary Janssen touted data today from a pivotal Phase III trial showing that Xarelto plus aspirin reduced the risk of major cardiovascular events in patients with stable coronary and peripheral artery disease compared to aspirin alone.
Treatment with Xarelto twice per day and aspirin once-daily cut the risk of major cardiovascular events by 24%, including a 42% reduction in strokes and a 22% reduction in cardiovascular death, the company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Xarelto, aspirin combo reduces risk of cardiovascular events in pivotal Ph3 trial appeared first on MassDevice.
from MassDevice http://ift.tt/2wM49jZ
Cap comentari:
Publica un comentari a l'entrada